While the NLR was associated with improved OS for the overall cohort in this study, the fact that NLR has been consistently shown to be associated with improved survival with anti-VEGF TKIs, mTOR inhibition, immunotherapy, and post-nephrectomy supports the notion that NLR is a prognostic biomarker in advanced RCC regardless of treatment type. The gene discussed is MTOR; the disease is renal cell carcinoma.